Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1278983 | 0.89 | KDM4E (0.58) | KMT2AMEN1PKMLMNAALDH1A1 | |
| SCHEMBL17832062 | 0.83 | PIK3CG (0.72) | KMT2AMEN1PKMLMNAALDH1A1 | |
| SCHEMBL29558921 | 0.76 | PIK3CG (0.47) | KMT2AMEN1PKMLMNAGAA | |
| SCHEMBL54882 | 0.76 | PIK3CG (0.47) | KMT2AMEN1PKMLMNAGAA | |
| SCHEMBL12050296 | 0.74 | BRPF1 (0.59) | — | |
| SCHEMBL2304056 | 0.73 | MAPT (0.52) | TP53 | |
| SCHEMBL29131219 | 0.73 | PKM (0.49) | KMT2AMEN1PKMLMNAALDH1A1 | |
| SCHEMBL3175230 | 0.73 | PKM (0.63) | KMT2AMEN1PKMLMNAALDH1A1 | |
| SCHEMBL4197942 | 0.72 | LMNA (0.57) | KMT2AMEN1PKMLMNAALDH1A1 | |
| SCHEMBL26090948 | 0.71 | PARG (0.64) | KMT2APKMLMNATP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118925-B | Preparation method and application of benzimidazole-2-ketone derivative | 中国人民解放军陆军军医大学 | 2025-05-27 | — | — | CN | disclosed |
| CN-119118925-A | Preparation method and application of benzimidazole-2-ketone derivative | 中国人民解放军陆军军医大学 | 2024-12-13 | — | — | CN | disclosed |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-110776494-B | Benzyl piperidine-benzimidazole derivative or pharmaceutically acceptable salt thereof, preparation method and application | 中国药科大学 | 2021-01-05 | — | — | CN | disclosed |
| CN-110776494-A | Benzyl piperidine-benzimidazole derivative or pharmaceutically acceptable salt thereof, preparation method and application | 中国药科大学 | 2020-02-11 | — | — | CN | disclosed |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | TBXA2R, PDE4D, PDE4A | KMT2A 3729/4885MEN1 2095/4885PKM 3148/4885 |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | KMT2A 1817/4885MEN1 2663/4885PKM 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.